ClinicalTrials.gg
RecruitingNCT06975748Updated Apr 7, 2026

A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

A Phase 2 interventional study of STSP-0902 ophthalmic solution and STSP-0902 ophthalmic solution in Neurotrophic Keratitis, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK). The study plans to enroll 48 patients with Mackie Stage 2 or 3 NK affecting one or both eyes. Eligible subjects will be randomized 1:1:1 into three dosing groups. Each dosing group will follow a drug-placebo allocation (12 active: 4 placebo). Treatment involves topical ocular administration for 8 weeks. Subjects who are not healed after the 8 weeks of masked treatment period will be permitted to receive standard of care during the follow-up period

02

Conditions studied

  • Neurotrophic Keratitis

Browse trials for

Keywords

  • STSP-0902
  • Ophthalmic Solution
  • Neurotrophic Keratitis
03

In context

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

This study's planned enrollment of 48 is above the median of 40 across 70 interventional studies indexed under Keratitis.

Browse Keratitis studies →

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged between 18 to 85 years (inclusive).
  2. Diagnosed with NK in one or both eyes, with the study eye classified as Mackie Stage 2 (PED) or Stage 3 (corneal ulcer), and with a maximum corneal defect diameter ≥2 mm.
  3. Reduced or absent corneal sensitivity in the defect area and at least 1 adjacent corneal quadrant, confirmed by: ≤40 mm using the aesthesiometer or cotton swab test demonstrating marked reduction or absence of corneal sensitivity.
  4. NK duration >2 weeks in the study eye, as confirmed by the investigator based on medical history.
  5. No improvement in the study eye for ≥7 days prior to randomization.
  6. Effective non-pharmacological used by the subject (and partner, if applicable) throughout the trial and for 3 months after the last dose, with no plans for pregnancy or gamete donation.
  7. Voluntarily sign , with willingness and ability to comply with study procedures, follow-ups, and assessments.

Exclusion criteria

Exclusion Criteria:

  1. Any eye with corneal stromal ulceration involving >1/3 of corneal thickness or at risk of corneal melting/perforation.
  2. Active infection (bacterial, viral, fungal, amoebic, chlamydial) in any eye, or active ocular inflammation unrelated to NK.
  3. Study eye with other ocular diseases requiring topical medication apart from the prescribed adjunctive treatments during the trial.
  4. Bilateral vision loss severely impacting daily life, as assessed by the investigator.
  5. Study eye with Schirmer I test ≤3 mm/5 minutes.
  6. Severe lagophthalmos, eyelid margin disease, or meibomian gland dysfunction in the study eye that may impair corneal healing or trial outcomes.
  7. Study eye with any surgery within 3 months prior to randomization (including corneal/non-corneal surgeries affecting trial assessments, except surgeries related to NK etiology), or planned ocular surgery during the trial.
  8. Study eye with prior surgical intervention for NK (e.g., tarsorrhaphy, conjunctival flap) that may confound efficacy assessments, or amniotic membrane transplantation within 6 weeks prior to randomization.
  9. Study eye with botulinum toxin injections to the levator muscle within 3 months prior to randomization or planned during the trial.
  10. Requirement to wear contact lenses during the trial.
  11. History of inefficacy or poor response to nerve growth factor (NGF) eye drops in any eye.
  12. Use of autologous serum eye drops, deproteinized calf blood extracts, or other growth factor-containing ocular medications in the study eye(s) planned during the trial.
  13. Use of NSAIDs, or in the study eye within 1 week prior to randomization or planned during the trial.
  14. Use of neurotoxic drugs (e.g., antipsychotics, antiepileptics, antihistamines) or systemic within 4 weeks prior to randomization or planned during the trial, excluding those who have been using it stably for at least 4 weeks before enrollment.
  15. Poorly controlled systemic or ocular conditions (e.g., diabetic retinopathy, uveitis, diseases, , psychiatric disorders) that may confound efficacy assessments or compliance, as judged by the investigator.
  16. Known to the study drug, its , or components of trial-related ophthalmic tests (e.g., fluorescein).
  17. History of drug abuse or alcohol dependence.
  18. Participation in another interventional trial (drugs, devices, or vaccines) within 3 months prior to randomization or planned during this trial.
  19. Female subjects who are pregnant, breastfeeding, or test positive for serum pregnancy; or who are failure to use effective for 2 weeks prior to screening, during the trial, or for 3 months post-dosing.
  20. Difficulty administering eye drops, venous blood sampling, or history of needle phobia/vasovagal syncope.
  21. Any other condition deemed unsuitable for trial participation by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Low Dose 3 Times Daily Arm

    Low dose of STSP-0902 ophthalmic solution to the affected eye(s), 3 times daily for 8 weeks

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Low Dose 6 Times Daily Arm

    Low dose of STSP-0902 ophthalmic solution to the affected eye(s), 6 times daily for 8 weeks

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    High Dose 3 Times Daily Arm

    High dose of STSP-0902 ophthalmic solution to the affected eye(s), 3 times daily for 8 weeks

    Drug: STSP-0902 ophthalmic solution

  • Placebo comparator
    Control Arm

    STSP-0902 Placebo to the affected eye(s), 3 or 6 times daily for 8 weeks

    Drug: STSP-0902 Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Number of participants with ocular and systemic adverse events as assessed by CTCAE v5.0.

    Time frame: Screening to Week 10

  2. Ocular Symptoms and Signs

    Number of subjects with clinically significant changes in ocular symptoms and signs.

    Time frame: Screening to Week 10

  3. Intraocular Pressure (IOP) Measurements

    Change in IOP is measured using a non-contact tonometer (In cases requiring precise IOP evaluation, a contact tonometer may be used).

    Time frame: Screening to Week 10

  4. Slit-Lamp Examinations

    Number of subjects with clinically significant changes detected by slit-lamp microscope. The slit lamp examinations will encompass the eyelids, conjunctiva, cornea, anterior chamber, aqueous humor, iris, lens, and other relevant ocular structures.

    Time frame: Screening to Week 10

  5. Optical Coherence Tomography (OCT) Results

    Proportion of corneal thickness affected by the stromal ulceration, as evaluated by the investigator.

    Time frame: Screening to Week 10

  6. Clinically Significant Changes in Vital Signs

    Vital signs include body temperature in ℃, pulse rate in bpm, respiration rate in breaths/ minute, and blood pressure in mmHg.

    Time frame: Screening to Week 10

  7. Clinically Significant Changes in Physical Examinations

    Physical examinations include assessments of general status, skin and mucous membranes, lymph nodes, head and neck, chest, abdomen, musculoskeletal system, spine/extremities, nervous system, and additional regions as clinically indicated.

    Time frame: Screening to Week 10

  8. Clinically Significant Changes in 12-Lead ECGs

    Parameters measured: Heart rate in bpm, P-R interval in ms, QRS duration in ms, QT interval in ms, QTc interval in ms.

    Time frame: Screening to Week 10

  9. Clinically Significant Laboratory Abnormalities

    Blood samples will be collected for hematology, blood biochemistry and coagulation function. Urine sample will be collected for and urinalysis.

    Time frame: Screening to Week 10

Secondary outcomes

  1. Corneal Healing

    Percentage of subjects achieving corneal healing assessed via corneal fluorescein staining by the investigator

    Time frame: Baseline to Week 10

  2. Corneal Sensitivity

    Evaluation of sensation in corneal quadrants using the aesthesiometer

    Time frame: Baseline to Week 10

  3. Patients with Deterioration

    Percentage of Subjects with Disease Deterioration

    Time frame: Baseline to Week 10

  4. Best Corrected Visual Acuity (BCVA)

    Change in BCVA from Baseline

    Time frame: Baseline to Week 8

  5. Tear Secretion

    Change in Tear Secretion from Baseline as evaluated via Schirmer I test

    Time frame: Baseline to Week 8

  6. Visual Quality of Life Assessed Using the NEI-VFQ-25

    VFQ-25 is a questionnaire composed of 25 vision-targeted questions assessing 11 vision-related constructs, along with a single-item question to rate general health. Original responses from the questionnaire are recoded to a scale ranging from 0 to 100, where a higher score indicates better visual function. Each question corresponds to one of the 12 sub-scales and scores for each sub-scale are calculated by averaging its constituent questions. The overall composite score is generated by averaging the 11 vision-specific sub-scales, excluding the general health item.

    Time frame: Baseline to Week 8

  7. STSP-0902 concentration

    Measurement of STSP-0902 in plasma after drug administration

    Time frame: Baseline to Week 10

  8. Incidence of positive detection of anti-STSP-0902 antibodies

    Measurement of anti-drug antibody (ADA) to STSP-0902 in plasma after drug administration

    Time frame: Baseline to Week 10

07

Study locations

1 of 1 sites recruiting
  • Shandong First Medical University Affiliated Eye Hospital
    Jinan, Shandong 250021, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
May 16, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06975748
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jun 12, 2025
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Wanchun Huai
Contact
huaiwanchun@staidson.com
+86-13311368335
Weiyun Shi, Ph.D
principal investigator · Shandong First Medical University Affiliated Eye Hospital
Ting Wang, Ph.D
principal investigator · Shandong First Medical University Affiliated Eye Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STSP-0902

Start the discussion